Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era

This publication has 70 references indexed in Scilit:

• Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
  New England Journal of Medicine, 2013
• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
  The Lancet Oncology, 2012
• Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
  New England Journal of Medicine, 2012
• Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
  Cancer Research, 2011
• Abiraterone and Increased Survival in Metastatic Prostate Cancer
  New England Journal of Medicine, 2011
• Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
  New England Journal of Medicine, 2010
• The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
  European Journal of Cancer, 2010
• Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
  Cancer Research, 2009
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
  Science, 2009
• Promoting apoptosis as a strategy for cancer drug discovery
  Nature Reviews Cancer, 2005